VILAZODONE • LEVOMILNACIPRAN • VORTIOXETINE

Prescriber’s guide to using 3 new antidepressants

How do they work? What makes them different? And which patients might benefit most from taking them?

Ahmed Z. Elmaadawi, MD
Narendra Singh, MD
Jagadeesh Reddy, MD, MPH
Adjunct Clinical Assistant Professors

Suhayl Joseph Nasr, MD
Volunteer Clinical Professor

Department of Psychiatry
Indiana University School of Medicine—South Bend Campus
South Bend, Indiana

Disclosures
Drs. Elmaadawi, Singh, and Reddy report no financial relationships with any company whose products are mentioned in this article or with manufacturers of competing products. Dr. Nasr is a member of the speakers’ bureau for Forest Pharmaceuticals and Takeda Pharmaceutical Company Limited and H. Lundbeck A/S.

With a prevalence >17%, depression is one of the most common mental disorders in the United States and the second leading cause of disability worldwide. For decades, primary care and mental health providers have used selective serotonin reuptake inhibitors (SSRIs) as first-line treatment for depression—yet the remission rate after the first trial of an antidepressant is <30%, and continues to decline after a first antidepressant failure. That is why clinicians continue to seek effective treatments for depression—ones that will provide quick and sustainable remission—and why scientists and pharmaceutical manufacturers have been competing to develop more effective antidepressant medications.

In the past 4 years, the FDA has approved 3 antidepressants—vilazodone, levomilnacipran, and vortioxetine—with the hope of increasing options for patients who suffer from major depression. These 3 antidepressants differ in their mechanisms of action from other available antidepressants, and all have been shown to have acceptable safety and tolerability profiles.

In this article, we review these novel antidepressants and present some clinical pearls for their use. We also present our observations that each agent appears to show particular advantage in a certain subpopulation of depressed patients who often do not respond, or who do not adequately respond, to other antidepressants.

continued on page 32
Vilazodone was approved by the FDA in 2011 (Table 1). The drug increases serotonin bioavailability in synapses through a strong dual action:

- blocking serotonin reuptake through the serotonin transporter
- partial agonism of the 5-HT1A presynaptic receptor.

Vilazodone also has a moderate effect on the 5-HT4 receptor and on dopamine and norepinephrine uptake inhibition.

The unique presynaptic 5-HT1A partial agonism of vilazodone is similar to that of buspirone: Both drugs initially inhibit serotonin synthesis and neuronal firing.

### Vilazodone

Vilazodone also has a moderate effect on the 5-HT4 receptor and on dopamine and norepinephrine uptake inhibition.

The unique presynaptic 5-HT1A partial agonism of vilazodone is similar to that of buspirone, in which both drugs initially inhibit serotonin synthesis and neuronal firing. Researchers therefore expected that vilazodone would be more suitable for patients who have depression and a comorbid anxiety disorder; current FDA approval, however, is for depression only.

#### Adverse effects.

The 5-HT4 receptor on which vilazodone acts is present in the gastrointestinal (GI) tract, and contributes to regulating symptoms in patients with irritable bowel syndrome (IBS); not surprisingly, the most frequent adverse effects of vilazodone are GI in nature (diarrhea, nausea, vomiting).

Headache is the most common non-GI side effect of vilazodone. Depressed patients who took vilazodone had no significant weight gain and did not report adverse sexual effects, compared with subjects given placebo.

The following case—a patient with depression, significant anxiety, and IBS—exemplifies the type of patient for whom we find vilazodone most useful.

**CASE** Ms. A, age 19, is a college student with a history of major depressive disorder, social anxiety, and panic attacks for 2 years and IBS for 3 years. She was taking lubiprostone for IBS, with incomplete relief of GI symptoms. Because the family history included depression in Ms. A’s mother and sister, and both were doing well on escitalopram, we began a trial of that drug, 10 mg/d, that was quickly titrated to 20 mg/d.

Ms. A did not respond to 20 mg of escitalopram combined with psychotherapy.

We then started vilazodone, 10 mg/d after breakfast, for the first week, and reduced escitalopram to 10 mg/d. During Week 2, escitalopram was discontinued and vilazodone was increased to 20 mg/d. During Week 3, vilazodone was titrated to 40 mg/d.

Ms. A tolerated vilazodone well. Her depressive symptoms improved at the end of Week 2.

Unlike her experience with escitalopram, Ms. A’s anxiety symptoms—tenseness, racing thoughts, and panic attacks—all diminished when she switched to vilazodone. Notably, her IBS symptoms also were relieved, and she discontinued lubiprostone.

Ms. A’s depression remained in remission for 2 years, except for a brief period one summer, when she thought she “could do without any medication.” She tapered the vilazodone, week by week, to 10 mg/d, but her anxiety and bowel symptoms resurfaced to a degree that she resumed the 40-mg/d dosage.

### Levomilnacipran

This drug is a 2013 addition to the small serotonin–norepinephrine reuptake inhibitor (SNRI) family of venlafaxine, desvenlafaxine, and duloxetine (Table 2). Levomilnacipran is the enantiomer of milnacipran, approved in Europe for depression but only for fibromyalgia pain and peripheral neuropathy in the United States.

Levomilnacipran is unique because it is more of an NSRI, so to speak, than an...
SNRI: That is, the drug’s uptake inhibition of norepinephrine is more potent than its serotonin inhibition. Theoretically, levomilnacipran should help improve cognitive functions linked to the action of norepinephrine, such as concentration and motivation, and in turn, improve social function. The FDA also has approved levomilnacipran for treating functional impairment in depression.  

Adverse effects. The norepinephrine uptake inhibition of levomilnacipran might be responsible for observed increases in heart rate and blood pressure in some patients, and dose-dependent urinary hesitancy and erectile dysfunction in others. The drug has no significant effect on weight in depressed patients, compared with placebo.

The following case illustrates the benefits of levomilnacipran in a depressed patient who suffers from chronic pain and impaired social function.

CASE  Mrs. C, age 44, was referred by her outpatient psychologist and her primary care provider for management of refractory depression. She did not respond to an SSRI, an SNRI, or augmentation with bupropion and aripiprazole.

Mrs. C was on disability leave from work because of depression and cervical spine pain that might have been related to repetitive movement as a telephone customer service representative. She complained of loss of motivation, fatigue, and high anxiety about returning to work because of the many unhappy customers she felt she had to soothe.

Levomilnacipran was started at 20 mg/d for 2 days, then titrated to 40 mg/d for 5 days, 80 mg/d for 1 week, and 120 mg/d thereafter. Her previous antidepressants, fluoxetine and bupropion, were discontinued while levomilnacipran was titrated.

Mrs. C continued to receive weekly psychotherapy and physical therapy and to take tizanidine, a muscle relaxant, and over-the-counter medications for pain. Her Patient Health Questionnaire (PHQ-9) score declined from 13 when levomilnacipran was started to 5 at the next visit, 6 weeks later.

Within 4 months of initiating levomilnacipran, Mrs. C returned to work with a series of cue cards to use when speaking with irate or unhappy customers. At that point, her cervical spine pain was barely noticeable and no longer interfered with function.

Vortioxetine
This agent has a novel multimodal mechanism of action (Table 3, page 34). It is an SSRI as well as a 5-HT1A full agonist and 5-HT3 receptor antagonist. Vortioxetine also has an inhibitory effect on 5-HT7 and 5-HT1D receptors and partial agonism of 5-HT1B receptors.

The downstream effect of this multimodal action is an increase in dopamine, norepinephrine, and acetylcholine activity in the prefrontal cortex. These downstream effects are thought to help restore some cognitive deficits associated with depression.

Vortioxetine is the only antidepressant among the 3 discussed in this article that was studied over a long period to ensure that short-term benefits continue beyond the 6- to 8-week acute Phase-III studies. A high remission rate (61%) was observed in patients who were treated on an open-label basis with vortioxetine, 10 mg/d, then randomized to maintenance with vortioxetine or placebo.

Older patients. Vortioxetine is unique among these 3 antidepressants in that it is the only one studied separately in geriatric patients: In an 8-week Phase-III trial,
Novel antidepressants

Clinical Point

We have found that vortioxetine is helpful for depressed patients who have cognitive deficits—especially geriatric patients.

Table 3

<table>
<thead>
<tr>
<th>Fast facts: Vortioxetine</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Brand name</strong></td>
</tr>
<tr>
<td><strong>Class</strong></td>
</tr>
<tr>
<td><strong>FDA approval date</strong></td>
</tr>
<tr>
<td><strong>Manufacturer</strong></td>
</tr>
<tr>
<td><strong>Dosage forms</strong></td>
</tr>
<tr>
<td><strong>Recommended dosage</strong></td>
</tr>
</tbody>
</table>

452 geriatric patients age 64 to 88 were randomized to 5 mg/d of vortioxetine or placebo. Vortioxetine was significantly more effective than placebo at Week 6.

Vortioxetine also is the only antidepressant investigated for an effect on cognitive deficits: In a Phase-III double-blind, placebo-controlled study of 602 patients with major depressive disorder, using duloxetine as active reference, vortioxetine was found to have a significant effect on Digit Symbol Substitution Test scores, compared with placebo, independent of its antidepressant effect (ie, patients who did not show any antidepressant benefit still showed an improvement in attention, speed processing, memory, and executive function).

We have found, therefore, that vortioxetine is helpful for depressed patients who have cognitive deficits, especially geriatric patients.

**Case**

Mrs. B, age 84, married, has a 4-year history of depression. She has taken several antidepressants with little consistent relief.

A brief psychiatric hospitalization 2 years ago temporarily reduced the severity of Mrs. B’s depression; gradually, she relapsed. She felt hopeless and resisted another psychiatric evaluation. Mrs. B’s family includes several clinicians, who wondered if she was developing cognitive deficits that were interfering with her recovery.

At initial evaluation, Mrs. B failed to recall 2 of 3 objects but performed the clock drawing test perfectly—qualifying her for a diagnosis of mild cognitive impairment in addition to major depression. Her PHQ-9 score at baseline was 22.

On the assumption that the severity of her depression was contributing to cognitive deficits, vortioxetine, 5 mg/d, was initiated for 2 weeks and then titrated to 10 mg/d.

At 4 weeks’ follow-up, Mrs. B passed the Mini-Cog test; her PHQ-9 score fell to 8. She has remained asymptomatic for 6 months at the 10-mg/d dosage; her lowest PHQ-9 score was 5.

**Adverse effects**.

The most common adverse effects are mild or moderate GI in nature. Weight gain and adverse sexual effects were not significantly different among patients receiving vortioxetine than among patients given placebo.

A note about the safety of these agents

All 3 of these antidepressants carry the standard black-box warning about the elevated risk of suicide in patients taking an antidepressant. None of them are approved for patients age <18.

Suicidal ideation was reported in 11.2% of patients taking vortioxetine, compared with 12.5% of those given placebo; 24% of patients taking levomilnacipran reported suicidal ideation, compared with 22% of those who took placebo. In a long-term study of 599 patients taking vilazodone, 4 given placebo exhibited suicidal behavior, compared with 2 who took vilazodone.

Drug-drug interactions are an important consideration when vilazodone, levomilnacipran, and vortioxetine are prescribed in combination with other medications. See the following discussion.

**Vilazodone** should be taken with food because it has 72% bioavailability after a meal. The drug is metabolized primarily by cytochrome P (CYP) 3A4 and CYP3A5; it does not affect CYP substrates or, it’s likely, produce significant changes to other medications metabolized by the CYP pathway.

Conversely, the dosage of vilazodone should be reduced to 20 mg/d if it is co-
administered with a strong CYP3A4 inhibitor (eg, ketoconazole). The dosage should be increased as much as 2-fold when vilazodone is used concomitantly used with a strong CYP3A4 inducer (eg, carbamazepine) for >14 days. The maximum daily dosage should not exceed 80 mg/d.

**Levomilnacipran.** Unlike vilazodone and vortioxetine, levomilnacipran is affected by renal function. Concomitant medications, however, including those that influence CYP renal transporters (particularly CYP3A4, which metabolizes levomilnacipran), do not show an impact on the blood level of levomilnacipran.

No dosage adjustment is needed for patients who have mild renal impairment, but the maintenance dosage of levomilnacipran for patients who have moderate or severe renal impairment should not exceed 80 mg/d in 1 dose, and 60 mg/d in 1 dose, respectively.

**Vortioxetine.** Seventy percent of a dose of vortioxetine is absorbed independent of food; the drug has a half-life of 66 hours. Vortioxetine is metabolized primarily by the CYP450 enzyme system, including 2D6, and, to a lesser extent, by CYP3A4, CYP3A5, CYP2C9, and CYP2C19.

Vortioxetine has minimal effect on P450 substrates in in vitro studies, which was confirmed in 4 other in vivo studies. In studies of hormonal contraception, bupropion, and omeprazole, vortioxetine did not produce significant changes in the blood level of the other medications. The blood level of vortioxetine increased by 128% when taken with the CYP2D6 inhibitor bupropion, but the blood level did not markedly change with other inhibitors because the drug utilizes uses several CYP pathways. Use caution, therefore, when adding bupropion to vortioxetine because the combination elevates the risk of nausea, diarrhea, and headache.

**With each agent, specific benefit**

Vilazodone, levomilnacipran, and vortioxetine each add distinct benefit to the clinician’s toolbox of treatments for major depressive disorder. Although all antidepressants to some extent alleviate anxiety and pain and reverse cognitive decline associated with depression, our experience suggests using vilazodone for anxious depressed patients; levomilnacipran for depressed patients who experience pain; and vortioxetine for depressed patients who suffer cognitive decline and for geriatric patients.

---

**Bottom Line**

The FDA has approved 3 antidepressants in the past 4 years: vilazodone, levomilnacipran, and vortioxetine. The hope is that these agents will bolster treatment options for major depression—perhaps especially so, as we have seen, in the anxious depressed (vilazodone), the depressed in pain (levomilnacipran), and the depressed with cognitive decline, or geriatric patients (vortioxetine).
Clinical Point
Use caution when adding bupropion to vortioxetine because the combination elevates the risk of nausea, diarrhea, and headache.